ALK-Positive

ALK-Positive

First-Line Lorlatinib Improves Survival and Metastasis in Advanced ALK-Positive Lung Cancer

Rebecca AraujoNon-Small Cell Lung Cancer | November 19, 2020

Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...

FDA Approves New Treatment for ALK-Positive Metastatic NSCLC

Kerri FitzgeraldALK+ NSCLC | November 5, 2018

The U.S. Food and Drug Administration approved lorlatinib for patients with ALK-positive metastatic non-small cell ...

Latest News

Testing Category 1

August 29, 2025

Guided by Data: Navigating Biopsies, Biomarkers, and Treatment Strategies in NSCLC

August 13, 2025

From Screening to Strategy: Navigating the First Steps in Lung Cancer Care

August 12, 2025

FDA Grants Accelerated Approval to Zongertinib for NSCLC With HER2 TKD-Activating Mutations

August 11, 2025

Surgery for NSCLC: Multidisciplinary Panel Discusses Operative Considerations

August 11, 2025

Managing Side Effects in Patients With NSCLC: Experts Share Strategies

August 11, 2025

Physician's Weekly

Family Practice

FDA Approves Gardenia-Based Blue Dye for Use in Foods and Drinks

Family Practice

Most Major Ice Cream Brands Will Remove Synthetic Dyes by 2028

Dermatology

Atopic Dermatitis May Be Linked to Increased Risk for CKD